Positive RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025 Entered Collaboration with William Demant Invest to Develop ReSonance™ (ANP1) for ...
CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological ...
Lineage Cell Therapeutics (AMEX:LCTX) will release its quarterly earnings report on Tuesday, 2025-05-13. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Lineage ...
Lineage Cell Therapeutics, Inc. ((LCTX)) has held its Q3 earnings call. Read on for the main highlights of the call. Lineage Cell Therapeutics Faces Mixed Sentiments Amidst Progress and Financial ...
Novel engineered iPS cell line to be evaluated by Lineage for potential development of cell transplant therapies for central nervous system diseases under collaboration initiated in early 2023 Lineage ...
In this article, we will be taking a look at the 15 Best Biotech Penny Stocks to Invest in Right Now. Lineage Cell Therapeutics, Inc. is one of them. Lineage Cell Therapeutics, Inc. (NYSE:LCTX) is a ...
Lineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
CARLSBAD, Calif.--(BUSINESS WIRE)-- Lineage Cell Therapeutics, Inc. (LCTX) (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell ...
Russo Partners – Media Relations Nic Johnson or David Schull ([email protected]) ([email protected]) (212) 845-4242 Source: Lineage Cell Therapeutics, Inc. The views and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results